Form D · Biotechnology

SANGART INC

San Diego, CA · CIK 0001171476

Offering snapshot reported May 24, 2012 · SEC filing

Reported sold: $101M
Investors reported: 0
Minimum accepted: $1
First sale: Mar 30, 2011

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$50,037,285 → $100,774,578
Reported investors3 → 0

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 24, 2012	Amendment	$100,774,578	$50,737,293vs Apr 15, 2011	0	SEC filing
Apr 15, 2011	Initial	$50,037,285	No comparison	3	SEC filing
Oct 13, 2010	Initial	$15,098,381	No comparison	10	SEC filing
Mar 16, 2007	Paper	Not reported	No comparison	Not reported	SEC filing
Aug 21, 2006	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity
Exemptions: 06
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-158472

Source: Form D, filed May 24, 2012. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Ian Cumming	Director
John Eyring	Director
Brian O'callaghan	Director, Executive
David Renas	Executive
Joseph Steinberg	Director
Justin Wheeler	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

6175 Lusk Boulevard
San Diego, CA, 92121